InvestSMART

Dimerix Limited (ASX: DXB) - Announcements

- Current share price for DXB : $0.235

ASX company news and announcements for Dimerix Limited (DXB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Dimerix Limited (DXB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Dimerix Limited (DXB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Dimerix Limited (DXB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$138 Application for quotation of securities - DXB 5 Jun 2025 3:47PM $0.568 $0.230 fallen by 59.47%
$138 Application for quotation of securities - DXB 3 Jun 2025 11:38AM $0.570 $0.230 fallen by 59.65%
$138 1st ACTION3 site in Japan activated and milestone triggered 30 May 2025 8:26AM $0.570 $0.230 fallen by 59.65%
$138 Application for quotation of securities - DXB 29 May 2025 1:28PM $0.570 $0.230 fallen by 59.65%
$138 Notification of upcoming expiry of Listed Options 29 May 2025 9:25AM $0.585 $0.230 fallen by 60.68%
$138 Application for quotation of securities - DXB 27 May 2025 2:02PM $0.610 $0.230 fallen by 62.30%
$138 Application for quotation of securities - DXB 22 May 2025 11:53AM $0.600 $0.230 fallen by 61.67%
$138 Successful planned IDMC review of ACTION3 trial 22 May 2025 8:31AM $0.590 $0.230 fallen by 61.02%
$138 Change in substantial holding 20 May 2025 1:07PM $0.575 $0.230 fallen by 60%
$138 Application for quotation of securities - DXB 20 May 2025 1:06PM $0.575 $0.230 fallen by 60%
$138 Dimerix to present at Melbourne Twilight Investor Briefing 20 May 2025 9:33AM $0.560 $0.230 fallen by 58.93%
$138 Application for quotation of securities - DXB 16 May 2025 11:31AM $0.610 $0.230 fallen by 62.30%
$138 Application for quotation of securities - DXB 14 May 2025 12:58PM $0.595 $0.230 fallen by 61.34%
$138 Application for quotation of securities - DXB 12 May 2025 1:09PM $0.615 $0.230 fallen by 62.60%
$138 Application for quotation of securities - DXB 8 May 2025 3:19PM $0.715 $0.230 fallen by 67.83%
$138 Dimerix receives initial upfront payment from Amicus 6 May 2025 8:27AM $0.700 $0.230 fallen by 67.14%
$138 Application for quotation of securities - DXB 1 May 2025 2:20PM $0.720 $0.230 fallen by 68.06%
$138 Investor Webinar and Presentation 1 May 2025 9:22AM $0.480 $0.230 fallen by 52.08%
$138 Dimerix Licenses DMX-200 in the US 1 May 2025 9:10AM $0.480 $0.230 fallen by 52.08%
$138 Quarterly Appendix 4C and Activities Report 30 Apr 2025 12:01PM $0.480 $0.230 fallen by 52.08%
$138 Trading Halt 29 Apr 2025 8:31AM $0.480 $0.230 fallen by 52.08%
$138 Application for quotation of securities - DXB 28 Apr 2025 2:43PM $0.480 $0.230 fallen by 52.08%
$138 FDA confirms Proteinuria as Primary Endpoint for US approval 28 Apr 2025 8:32AM $0.455 $0.230 fallen by 49.45%
$138 Application for quotation of securities - DXB 22 Apr 2025 1:45PM $0.413 $0.230 fallen by 44.24%
$138 Application for quotation of securities - DXB 16 Apr 2025 2:54PM $0.415 $0.230 fallen by 44.58%

76 - 100 of 736 results

Page 4 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.